Morgan Stanley raised CSR (01766.HK) 0.000 (0.000%) 's
2014-2015 earnings forecasts by 11% and 6%, and lifted its target price
from $8.4 to $9.3 to reflect the robust results in the third quarter.
Rating was maintained at Overweight as the broker expected that the
company might benefit from the potential integration of the industry.
BASETROPHY GP (08460.HK) Expects Jan-Aug Results to Swing to Loss BASETROPHY GP (08460.HK) -0.013 (-8.280%) issued a profit warning. The group is expected to record a loss for the eight months ended 31 August 2017 as compared with a net profit for the same period of 2016, mainly due to the decrease in revenue recognised by the group and increase of listing expense
Comments
Post a Comment